We acted as advisor to Biovian in a EUR 50 million manufacturing facility project in Turku, Finland. The new facility to be constructed in connection with the project will cover an area of 6,400 sqm and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products). It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The construction project is expected to be completed in December 2024.
Biovian is a globally operating GMP (Good Manufacturing Practice) contract development and manufacturing organisation (CDMO) of biopharmaceuticals, providing development and manufacturing services from early stage to finished product. Biovian is especially focusing on viral vector production, microbial production of recombinant proteins and GMP plasmid DNA.